Pollens - grasses, bermuda grass cynodon dactylon - Biologic Drug Details

Summary for pollens - grasses, bermuda grass cynodon dactylon

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, bermuda grass cynodon dactylon

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, bermuda grass cynodon dactylon Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, bermuda grass cynodon dactylon Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, bermuda grass cynodon dactylon Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Bermuda Grass Cynodon Dactylon-Based Biologic Drugs

Last updated: February 12, 2026

Market Overview

Bermuda grass (Cynodon dactylon) has gained attention for its potential in immunotherapy and allergy treatment. Its use in biologic drugs aims to address allergies to grasses and pollens, with substantial niche growth expected in allergy immunotherapy markets.

Demand Drivers

• Increasing prevalence of seasonal and perennial grass allergies globally.
• Growing awareness and acceptance of allergy immunotherapy (AIT).
• Pharmacological research supporting the efficacy of grass pollen extracts.
• Expansion into emerging markets with increasing healthcare infrastructure investment.

Market Size and Growth

The global allergy immunotherapy market was valued at approximately USD 6.2 billion in 2021. It is projected to grow at a Compound Annual Growth Rate (CAGR) of around 7% from 2022 to 2027, driven partly by grass pollen-based therapies, including Bermuda grass.

Key Segments

Segment	Market Share (2022)	Growth Rate (2022-2027)	Notes
Subcutaneous immunotherapy	65%	6.5%	Standard route for many grass pollen extracts
Sublingual immunotherapy	35%	8.4%	Growing body of research supports expansion

Competitive Landscape

Major players include:

• Stallergenes Greer
• HollisterStier
• Henry Schein
• Allergy Laboratories

New entrants focusing on Bermuda grass are forming collaborations with biotech firms for extract standardization and novel delivery systems.

Regulatory Pathway

• US FDA approval via Biologics License Application (BLA).
• European Medicines Agency (EMA) approval processes.
• Clinical trials focus on safety, efficacy, and standardization of Bermuda grass extracts.

Manufacturing and Sourcing

• Cultivation of Bermuda grass is scalable in warm climates.
• Standardization challenges include quality control over allergen content.
• Extracts are processed for stability, potency, and safety.

Financial Trajectory

Projected revenues for Bermuda grass-based biologics remain niche but growth-oriented, with potential milestones:

• Early R&D investments average USD 50-70 million globally.
• Substantial investments in clinical trials per indication, typically USD 20-40 million per phase.
• Breakthrough therapies or FDA approvals could accelerate commercialization timelines.
• Potential market entry around 2025-2026, with initial revenues in the USD 100 million range, scaling to over USD 500 million by 2030 with broad adoption.

Pricing and Reimbursement

• Current allergy immunotherapy treatments range from USD 150 to USD 400 per year per patient.
• Bermuda grass-based biologics priced similarly but may command higher premiums if clinical efficacy is established.
• Reimbursement policies vary; insurers increasingly cover allergen immunotherapy due to long-term cost savings.

Market Challenges

• Standardization and reproducibility of allergen extracts.
• Competition from existing grass pollen therapies.
• Regulatory hurdles delaying approval timelines.
• Market penetration barriers in regions with low awareness.

Key Performance Indicators (KPIs)

• Clinical trial success rates.
• Approval acquisition.
• Time to market.
• Market penetration in targeted regions.
• Patient adherence rates.

Summary

The Bermuda grass Cynodon dactylon biologic drug market is in a developmental phase, with growth driven by rising allergy prevalence and immunotherapy acceptance. The financial outlook suggests promising incremental revenues starting in the mid-2020s, contingent upon successful clinical trials and regulatory approvals. Standardization and regulatory pathways represent significant hurdles. The market remains competitive, with established players and new entrants seeking differentiation.

Key Takeaways

• Bermuda grass-based biologics target a growing segment within allergy immunotherapy.
• Clinical development and regulatory approval timelines are critical determinants of financial trajectory.
• The market is projected to grow at a CAGR of approximately 7% from 2022 to 2027.
• Reimbursement and pricing strategies will influence adoption rates.
• Standardization of allergen extracts remains a key challenge impacting commercialization.

FAQs

1. What is the primary advantage of Bermuda grass Cynodon dactylon in biologic drugs?
   It offers a targeted approach to grass pollen allergies, with potential for increased efficacy and reduced adverse reactions compared to non-standardized extracts.

2. What regulatory challenges face Bermuda grass-based biologics?
   Securing approvals requires demonstrating safety, efficacy, and reproducibility, often necessitating extensive clinical trials and standardization efforts.

3. How does the market size for Bermuda grass biologics compare to broader allergy therapies?
   It is a niche within the USD 6.2 billion global allergy immunotherapy market, with potential to expand significantly if clinical success and regulatory approvals occur.

4. When is commercial availability expected for Bermuda grass biologic drugs?
   Projected around 2025-2026, depending on clinical trial outcomes and regulatory review processes.

5. What strategies could accelerate market adoption?
   Standardizing allergen extracts, conducting substantive clinical trials, establishing reimbursement pathways, and forming collaborations with regional distributors.

Sources
[1] MarketsandMarkets, "Allergy Immunotherapy Market," 2022.
[2] Grand View Research, "Global Allergy Diagnostics and Immunotherapy Market," 2021.
[3] FDA, "Guidance for Industry: Developments in Allergen Extract Standardization," 2019.